JP2017519762A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519762A5
JP2017519762A5 JP2016573549A JP2016573549A JP2017519762A5 JP 2017519762 A5 JP2017519762 A5 JP 2017519762A5 JP 2016573549 A JP2016573549 A JP 2016573549A JP 2016573549 A JP2016573549 A JP 2016573549A JP 2017519762 A5 JP2017519762 A5 JP 2017519762A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
polypeptide
human
composition according
vwf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016573549A
Other languages
English (en)
Japanese (ja)
Other versions
JP6688746B2 (ja
JP2017519762A (ja
Filing date
Publication date
Priority claimed from NL2013007A external-priority patent/NL2013007B1/en
Application filed filed Critical
Publication of JP2017519762A publication Critical patent/JP2017519762A/ja
Publication of JP2017519762A5 publication Critical patent/JP2017519762A5/ja
Application granted granted Critical
Publication of JP6688746B2 publication Critical patent/JP6688746B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016573549A 2014-06-16 2015-06-16 免疫グロブリン単一可変ドメインでttpを処置する方法、およびその使用 Active JP6688746B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NL2013007A NL2013007B1 (en) 2014-06-16 2014-06-16 Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013007 2014-06-16
US201462030817P 2014-07-30 2014-07-30
US62/030,817 2014-07-30
PCT/EP2015/063493 WO2015193326A1 (en) 2014-06-16 2015-06-16 Methods of treating ttp with immunoglobulin single variable domains and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020014229A Division JP7105260B2 (ja) 2014-06-16 2020-01-30 免疫グロブリン単一可変ドメインでttpを処置する方法、およびその使用

Publications (3)

Publication Number Publication Date
JP2017519762A JP2017519762A (ja) 2017-07-20
JP2017519762A5 true JP2017519762A5 (enExample) 2019-01-17
JP6688746B2 JP6688746B2 (ja) 2020-04-28

Family

ID=51541255

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016573549A Active JP6688746B2 (ja) 2014-06-16 2015-06-16 免疫グロブリン単一可変ドメインでttpを処置する方法、およびその使用
JP2020014229A Active JP7105260B2 (ja) 2014-06-16 2020-01-30 免疫グロブリン単一可変ドメインでttpを処置する方法、およびその使用
JP2022110921A Pending JP2022160431A (ja) 2014-06-16 2022-07-11 免疫グロブリン単一可変ドメインでttpを処置する方法、およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020014229A Active JP7105260B2 (ja) 2014-06-16 2020-01-30 免疫グロブリン単一可変ドメインでttpを処置する方法、およびその使用
JP2022110921A Pending JP2022160431A (ja) 2014-06-16 2022-07-11 免疫グロブリン単一可変ドメインでttpを処置する方法、およびその使用

Country Status (15)

Country Link
US (5) US10858445B2 (enExample)
EP (6) EP3332800B1 (enExample)
JP (3) JP6688746B2 (enExample)
KR (2) KR102403388B1 (enExample)
CN (1) CN106559985A (enExample)
AU (2) AU2015276237B2 (enExample)
CA (1) CA2952103A1 (enExample)
ES (5) ES2843642T3 (enExample)
IL (1) IL249540B (enExample)
NL (1) NL2013007B1 (enExample)
PL (5) PL3335723T3 (enExample)
PT (5) PT3366305T (enExample)
RU (1) RU2704444C2 (enExample)
SG (2) SG11201610488QA (enExample)
WO (1) WO2015193326A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
CN107340225B (zh) * 2017-07-13 2019-07-05 徐州医科大学 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法
CN111670202A (zh) 2018-02-06 2020-09-15 埃博灵克斯股份有限公司 以免疫球蛋白单可变结构域治疗ttp初次发作的方法
CA3201986A1 (en) * 2020-11-18 2022-05-27 Green Cross Corporation Adamts13 variant having increased escaping rate or activity against autoantibody
US20240401239A1 (en) 2021-09-17 2024-12-05 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
WO2023108095A1 (en) * 2021-12-10 2023-06-15 Emory University Polypeptides that bind to von willebrand factor (vwf) al domain or an autoinhibitory module, variants, and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB335768A (en) 1929-10-24 1930-10-02 Jacoviac Maurice Improvements in protecting devices for gramophone disc records
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
JP2002535993A (ja) 1999-02-05 2002-10-29 リイクスニフェルシタイト ライデン 組換え体細胞における代謝物の生合成を変調する方法
IL147920A0 (en) 1999-08-02 2002-08-14 Keygene Nv Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2004015425A1 (en) 2002-08-07 2004-02-19 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
WO2004037999A2 (en) 2002-10-23 2004-05-06 Ludwig Institute For Cancer Research A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
RU2524129C2 (ru) 2003-01-10 2014-07-27 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
KR20050092029A (ko) 2003-01-10 2005-09-16 아블린쓰 엔.브이. 폰 빌레브란트 인자(vWF) 또는 콜라겐에 대한낙타과로부터의 재조합 VHH 단일 도메인 항체
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
AU2003264053A1 (en) 2003-08-12 2005-03-10 William M. Yarbrough Treatment for acne vulgaris and method of use
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
ATE473446T1 (de) 2005-01-14 2010-07-15 Ablynx Nv Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind
NZ563392A (en) * 2005-05-20 2009-12-24 Ablynx Nv Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
CA2678218A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
US8623361B2 (en) 2007-05-24 2014-01-07 Ablynx N.V. Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
CN101977654A (zh) 2008-03-21 2011-02-16 埃博灵克斯股份有限公司 冯威勒布兰特因子特异性结合物及其应用方法
WO2010077422A2 (en) 2008-10-29 2010-07-08 Wyeth Llc Formulations of single domain antigen binding molecules
KR20110079693A (ko) 2008-10-29 2011-07-07 와이어쓰 엘엘씨 단일 도메인 항원 결합 분자의 정제 방법
EP2506874A1 (en) 2009-12-01 2012-10-10 Ablynx N.V. Von willebrand factor specific binding agents and uses thereof
SI3757126T1 (sl) * 2010-11-05 2025-12-31 Novartis Ag Postopki za zdravljenje psoriatičnega artritisa z antagonisti il-17
DK3412305T3 (da) 2011-06-10 2021-03-01 Baxalta GmbH Behandling af koagulationssygdom ved administration af rekombinant vwf
EA027160B1 (ru) 2011-08-17 2017-06-30 Глаксо Груп Лимитед Модифицированные белки и пептиды
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
CN111670202A (zh) 2018-02-06 2020-09-15 埃博灵克斯股份有限公司 以免疫球蛋白单可变结构域治疗ttp初次发作的方法

Similar Documents

Publication Publication Date Title
JP2017519762A5 (enExample)
JP2017503820A5 (enExample)
JP2018111728A5 (enExample)
JP2018184417A5 (enExample)
JP2015529225A5 (enExample)
JP2018193377A5 (enExample)
JP2015517488A5 (enExample)
JP2020518599A5 (enExample)
JP2016512248A5 (enExample)
JP2015527402A5 (enExample)
JP2015518818A5 (enExample)
JOP20200156A1 (ar) إيسكيتامين لعلاج الاكتئاب
JP2014515763A5 (enExample)
JP2019519519A5 (enExample)
JP2013533858A5 (enExample)
JP2016529255A5 (enExample)
JP2017031213A5 (enExample)
JP2016513075A5 (enExample)
FI3227675T3 (fi) Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
JP2018509388A5 (enExample)
JP2014169326A5 (enExample)
JP2020521797A5 (enExample)
JP2012518624A5 (enExample)
JP2018505882A5 (enExample)
JP2012193216A5 (enExample)